| Open Document File Size: 219,51 KBShare Result on Facebook
City EQ / / Company Patient Access Scheme Assessment Group / Gilead Sciences Ltd. / Advisory Group / PFS Subgroup / / Country United States / Scotland / / Currency pence / GBP / / Event FDA Phase / / IndustryTerm above product / cancer therapy / pharmaceutical / treatment of patients with high risk disease / treatment of advanced active disease / food / / MedicalCondition refractory disease / leukemia / pneumonia / measurable disease / cancer / disease / dyspnea / chills / shock / chronic / cellulitis / neutropenia / high risk disease / nausea / thrombocytopenia / lymphocytosis / colitis / leukaemia / vomiting / fatigue / Chronic Lymphocytic Leukaemia / cough / illness / constipation / pneumonitis / infections / rash / severe neutropenia / sepsis / / MedicalTreatment chemo / immunotherapies / chemotherapy / radiotherapy / antibody therapy / immunotherapy / chemotherapies / cancer therapy / anticancer therapies / / Organization British Committee / NHS / / Position Vice Chairman / physician / / Product Methylprednisolone / 150mg / cyclophosphamide / pentostatin / US-312-0116 / / Technology diagnostic tests / antibodies / chemotherapy / treating cancer / transplantation / MRI / /
SocialTag |
idelalisib 100mg and 150mg tablets (Zydelig®) Gilead Sciences Ltd. SMC No[removed]February 2015